Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Biotech M&A is on the upswing. Here are the latest deals.
WEBAug 13, 2024 · Inside the market of emerging biotech. New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at …
Gilead wins approval of CAR-T therapy in adult leukemia
WEBOct 4, 2021 · Gilead’s cancer cell therapy Tecartus is now approved in the U.S. to treat adults with acute lymphoblastic leukemia, the treatment’s second clearance by the Food and Drug Administration and the first for a so-called CAR-T drug in people with the blood cancer who are older than 25. The approval, announced by Gilead’s Kite Pharma unit on ...
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB5 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
Biotech stock fundings headed for best quarter in 3 years, Jefferies ...
WEBMar 11, 2024 · Data the firm published over the weekend show biotech is on pace to post its highest quarterly total in three years, potentially exceeding the $11 billion companies raised in follow-on stock offerings in the first quarter of 2021. The average size of those financings increased from $167 million in January to $191 million in February, the report ...
A decade later, biotech’s CRISPR revolution is still going strong
WEBOct 11, 2023 · A cell and an injection needle are projected onto a screen during a CRISPR/Cas9 experiment in Berlin, Germany, on May 22, 2018. A research paper published a decade ago touched off a biomedical revolution that has made careers, spawned companies and drawn billions of dollars of investment. By the end of the year, the gene editing technology that ...
Biotech News - BioPharma Dive
WEBSep 13, 2024 · ArsenalBio raises $325M in one of the year’s largest biotech funding rounds. The financing comes amid a slowdown in venture investment for gene and cell therapy startups, and will support multiple solid tumor programs. …
The next era of Greater Boston’s biotech boom | BioPharma Dive
WEBNov 22, 2022 · The next era of Greater Boston’s biotech boom. Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs. Published November 22, 2022 • By Karissa Waddick , Shaun Lucas and Julia Himmel. A map of the Kendall Square neighborhood in ...
BridgeBio sends rare disease drugs to new company
WEBAug 21, 2024 · BridgeBio Pharma has transferred several preclinical and early clinical-stage drugs to a new company, GondolaBio, that’s drawn $300 million in promised investment from a syndicate of blue-chip life sciences investors. Viking Global Investors, Patient Square Capital and Frazier Life Sciences are among the investors backing GondolaBio ...